Serotonin-norepinephrine reuptake inhibitors and the risk of acute kidney injury (Q12-08)

Serotonin-norepinephrine reuptake inhibitors and the risk of acute kidney injury (Q12-08)

Q12-08

Overview

What is the issue?
  • SNRIs and SSRIs are classes of antidepressants that have been shown to be better tolerated than other antidepressants.
  • However, a series of 16 spontaneous reports of AKI in people using the SNRI duloxetine were identified in the Canada Vigilance database and 157 reports were identified in the World Health Organization (WHO) Adverse Reaction Database. Similar cases of AKI were reported with the two other SNRIs, venlafaxine and desvenlafaxine.
What was the aim of the study?
  • The primary aim of this study, conducted by the Canadian Network for Observational Drug Effect Studies (CNODES), was to determine if using SNRIs was associated with an increased risk of hospitalization for AKI, compared to using SSRIs in patients without kidney disease.
  • The secondary aim was to examine the risk of AKI associated with each SNRI drug.
How was the study conducted?
  • CNODES investigators identified 557,476 new users of SNRIs and 2,698,050 new users of SSRIs from eight administrative databases from Canada, the United States, and the United Kingdom.
  • Up to ten controls were randomly selected and matched to each case of AKI. The number of new cases of AKI in SNRI users was then compared to the number of new cases in SSRI users. A total of 38,974 cases of AKI were matched to 384,034 controls.
What did the study find?
  • Using SNRIs was not associated with an increased risk of hospitalization for AKI compared to SSRIs.
  • Using the SNRIs venlafaxine and desvenlafaxine was not associated with an increased risk of AKI, but using duloxetine was associated with a 16% increased risk. However, this result was not statistically significant and was explained by the fact that more people with diabetes tend to use this SNRI over other antidepressants.
  • CNODES has the ability to analyze a large amount of anonymous patient data to reliably assess questions of drug safety and effectiveness.
Implications
  • Physicians may not need to consider the risk of AKI when choosing between prescribing SNRIs versus SSRIs.
Key message
  • This CNODES study found that using serotonin-norepinephrine reuptake inhibitors (SNRIs) is not associated with an increased risk of hospitalization for acute kidney injury (AKI), when compared to selective serotonin reuptake inhibitors (SSRIs).

Manuscripts

Renoux C, Lix LM, Patenaude V, Bresee LC, Paterson MJ, Lafrance JP, Tamim H, Mahmud SM, Alsabbagh W, Hemmelgarn B, Dormuth CR, Ernst P, and the CNODES investigators. Serotonin-norepinephrine reuptake inhibitors and the risk of acute kidney injury: a cohort study of eight administrative databases and meta-analysis. CJASN. 2015 Oct 7;10(10):1716-22.

Presentations

Project Team

Methods Lead
Lisa Lix BSHEc, MSc, PhD, P Stat
Manitoba
Content Expert
Brenda Hemmelgarn MD, PhD, FRCPC
Alberta
Lead Analyst
Valerie Patenaude MSc
Site Investigator
Wasem Alsabbagh
Saskatchewan
Site Investigator
Gary Teare DVM, MSc, PhD
Saskatchewan
Site Investigator
Jean-Philippe Lafrance MD, FRCPC, MSc
Quebec
Site Investigator
Michael Paterson MSc
Ontario
Site Investigator
Hala Tamim PhD
Atlantic
Site Investigator
Colin R. Dormuth ScD
MarketScan
Site Investigator
Salah Mahmud MD MSc PhD FRCP(c)
Manitoba
Site Investigator
Christel Renoux PhD
CPRD
Site Investigator
Lauren Bresee PhD
Alberta
Analyst
Nianping Hu PhD
Saskatchewan
Analyst
Naoual Elftouh
Quebec
Analyst
Fangyun Wu MSc
Ontario
Analyst
Steve Doucette MSc
Atlantic
Analyst
Yan Wang MSc
Atlantic
Analyst
Anat Fisher MD, PhD
MarketScan
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Valerie Patenaude MSc
CPRD
Analyst
Jianguo (James) Zhang MSc
Alberta
Analyst
Zhihai Ma
Alberta